Biocorrx (BICX) Stock Price, News & Analysis

Company Overview

BioCorRx Inc. develops addiction treatment programs and related products designed to support individuals seeking recovery from alcohol and substance use disorders. The company’s offerings include the BioCorRx Recovery Program, which combines an initial detoxification protocol with counseling, behavioral support and ongoing recovery services. BioCorRx describes the program as non-addictive and designed to be delivered through qualified treatment providers.

The company also develops and markets nutritional supplements intended to support recovery and help address cravings and related wellness needs. Its product portfolio has included the UnBuzzed line and other supplements associated with alcohol-recovery support. BioCorRx licenses its recovery program and related intellectual property to independent providers, allowing treatment centers and practitioners to offer the program under the BioCorRx model.

BioCorRx serves customers primarily through a network of licensed treatment providers and healthcare professionals in the United States. The company is headquartered in California. Lourdes Felix has served as BioCorRx’s chief executive officer and has been associated with the company’s development and expansion of its addiction-recovery programs.

Key Stats

• Today's Range: $0.23 to $0.23
• 50-Day Range: $0.15 to $0.35
• 52-Week Range: $0.15 to $1.28
• Volume: 700 shs
• Average Volume: 1,024 shs
• Market Capitalization: $6.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Biocorrx Stock Analysis - MarketRank™

Biocorrx scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Biocorrx.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biocorrx is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biocorrx is -1.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Biocorrx has been sold short.

Short Interest Ratio / Days to Cover

Biocorrx has a short interest ratio ("days to cover") of 2.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biocorrx has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biocorrx does not currently pay a dividend.

Dividend Growth

Biocorrx does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Biocorrx has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Biocorrx this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biocorrx insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.40% of the stock of Biocorrx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Biocorrx has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BICX
• CIK: 1443863
• Web: www.biocorrx.com
• Phone: (714) 462-4880
• Fax: N/A
• Employees: 3
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.44 million
• Net Margins: N/A
• Pretax Margin: -399.75%
• Return on Equity: N/A
• Return on Assets: -90.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $800 thousand
• Price / Sales: 8.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.47) per share
• Price / Book: -0.48

Miscellaneous

• Outstanding Shares: 30,220,000
• Free Float: 23,754,000
• Market Cap: $6.81 million
• Optionable: Not Optionable
• Beta: 0.19